Armis and TrueFort Announce Strategic Partnership
12.4.2023 15:00:00 EEST | Business Wire | Press release
Armis, the leading asset visibility and security company, today announced a strategic partnership and integration with TrueFort, the lateral movement protection company. This collaboration empowers customers by enriching the discovery, understanding, and enforcement of security policies for IT, Internet of Things (IoT), and operational technology (OT) environments.
“Customers have shared with us just how critical context is for them when it comes to understanding how applications are connected to specific assets, who owns these applications, and how important they are to the business,” said Brian Gumbel, President, Armis. “This partnership with TrueFort enables us to put in place better security and segmentation policies to increase operational resilience and we are pleased to bring our combined expertise to customers.”
Research has found that lateral movement is used in 60% of all attacks. This is a result of OT and IT environments typically being combined into one flat network. If security teams do not have full visibility here, malicious actors can target both environments and move undetected between the two.
“Enterprises today have a great challenge to identify, document, map, and separate applications in a secure and controlled way with high accuracy and integrity,” said Sameer Malhotra, CEO and Co-founder, TrueFort. “This is especially true in critical industries, such as manufacturing, utilities, healthcare, and financial services. Together, Armis and TrueFort can fully discover and map IT and OT environments to enforce intelligent policies that prevent unauthorized lateral movement.”
Together, TrueFort and Armis help customers to:
- Discover all connected assets on the network, including applications, devices, service accounts, and infrastructure within a day using existing agent and agentless technology.
- Understand workload behavior and map it to the applications to baseline normal operations, empowering users with full confidence in what to block, disable, and kill.
- Enforce by account and action or push enforcement to host firewalls with the TrueFort or existing EDR agent.
“It’s critical that we operate securely in order to focus on our core mission: to bring efficient and sustainable climate solutions to buildings, homes, and transportation,” said James Powell, CISO, Trane Technologies. “Armis and TrueFort individually have been tremendous partners to us, so as a customer of both, this collaboration and the extended capabilities and services we’ll benefit from are exciting.”
The RSA Conference 2023 theme this year is, Stronger Together. The TrueFort and Armis partnership embodies this sentiment. This year at the event, both organizations will come together for a joint presentation. To attend, please visit Armis booth S-1127 on Tuesday, April 25, 2023 at 2:00pm PT. To learn more about Armis at RSA Conference, please visit: https://www.armis.com/rsac-2023/
TrueFort is a member of the Armis Partner Experience (APEX) program. The mission of this program is to build long-term, strategic relationships between Armis and its partners, and to foster collaboration to serve customers in the best way possible. Apply here to become a partner.
About Armis
Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.
About TrueFort
TrueFort puts you in control of lateral movement across the data center and cloud. The TrueFort Cloud extends protection beyond network activity by shutting down the abuse of service accounts. Founded by former IT executives from Bank of America and Goldman Sachs, leading global enterprises trust TrueFort to deliver unmatched application environment discovery and microsegmentation for both identity and activity. For more information visit https://truefort.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005062/en/
Contact information
Media Contacts:
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
Marc Gendron
Marc Gendron PR for TrueFort
marc@mgpr.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom